Indolent Lymphoma

News from the FDA/CDC

FDA approves ibrutinib for refractory MZL

The Food and Drug Administration has approved ibrutinib for the treatment of patients with relapsed or refractory marginal zone lymphoma, the drug...

MD IQ

Pages